(Q24276089)

Ribavirin monotherapy for chronic hepatitis C

PubMed

volume

1

0 references

issue

6

0 references

page(s)

590-598

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-γ and provide a mechanism for enhanced synovial chemokine levels in septic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Mechanisms of action of ribavirin against distinct viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Effects of ribavirin on red blood cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Hematological and bone marrow effects of ribavirin in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin targets eIF4E dependent Akt survival signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

New developments in the induction and antiviral effectors of type I interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Intracellular GTP level determines cell's fate toward differentiation and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The 30th anniversary of quasispecies. Meeting on 'Quasispecies: past, present and future'.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

A new standard of care for the treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin improves early responses to peginterferon through improved interferon signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Lassa fever. Effective therapy with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Pathways to extinction: beyond the error threshold

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Prolonged therapy of chronic hepatitis C with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The anti-yellow fever virus activity of ribavirin is independent of error-prone replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Effects of Mutagenic and Chain-Terminating Nucleotide Analogs on Enzymes Isolated from Hepatitis C Virus Strains of Various Genotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Host-based ribavirin resistance influences hepatitis C virus replication and treatment response

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Regulation of mRNA Translation and Cellular Signaling by Hepatitis C Virus Nonstructural Protein NS5A

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Hepatitis C virus internal ribosome entry site-dependent translation in Saccharomyces cerevisiae is independent of polypyrimidine tract-binding protein, poly(rC)-binding protein 2, and La protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

The biological significance of purine salvage

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021

Antiviral therapy for hepatitis C virus: beyond the standard of care

1 reference

https://api.crossref.org/works/10.1016%2FJ.COVIRO.2011.10.030

7 January 2021